Aspirin Resistance Reversibility in Diabetic Patients

Phase 4UnknownNCT01935193

Azienda Ospedaliera San Giovanni Battista160 enrolled

Overview

The aim of the study is assessing the prevalence of aspirin resistance in a cohort of diabetic patients. Those found resistant has been undergone pharmacological tests using different drug formulations to investigate the reversibility of aspirin resistance.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

160

Conditions

Aspirin Resistance

Interventions

lysine acetylsalicylateDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * diabete mellitus type 2 * asa since 30 days at least * plts \>150000 and \<450000 Exclusion Criteria: * recent ACS (within 30 days) * anticoagulant therapy * haemorragic diathesis

Locations (1)

San Giovanni Battista Hospital

Torino, Italy

RECRUITING

Outcomes

Primary Outcomes

platelets aggregation assessed by two tests (PFA100 and VerifyNow)

diabetic patients found aspirin resistant receive and infusion of 288 mg of lysine acetylsalicylate and they are tested again 24 h after the infusion to investigate if aspirin resistance have been reversed.

Time frame: 24 hours

Secondary Outcomes

stability of aggregation state after the reversion of aspirin resistance using oral formulation of lysine acetylsalicylate

Time frame: 1 month

Central Contacts

Marta Bisi, MD

CONTACT

+393476985414 martadoro@hotmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.